These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12001746)

  • 1. Efficacy of raloxifene for treatment of menopause: a systematic review.
    Boyack M; Lookinland S; Chasson S
    J Am Acad Nurse Pract; 2002 Apr; 14(4):150-65. PubMed ID: 12001746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A; Adachi JD
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to manage the menopause following therapy for breast cancer. is raloxifene a safe alternative?
    Sismondi P; Biglia N; Roagna R; Ponzone R; Ambroggio S; Sgro L; Cozzarella M
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S74-6. PubMed ID: 11056328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of raloxifene on bone loss and fracture risk in the menopausal woman].
    Vignot E; Meunier PJ
    Contracept Fertil Sex; 1999 Dec; 27(12):858-60. PubMed ID: 10676043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis].
    Štěpán J; Rosa J; Pavelka K
    Vnitr Lek; 2016; 62(10):781-788. PubMed ID: 27900864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene: recent information on skeletal and non-skeletal effects.
    Gluck O; Maricic M
    Curr Opin Rheumatol; 2002 Jul; 14(4):429-32. PubMed ID: 12118180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
    Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
    Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of international clinical trials with raloxifene].
    Agnusdei D; Liu-Léage S; Augendre-Ferrante B
    Ann Endocrinol (Paris); 1999 Sep; 60(3):242-6. PubMed ID: 10520416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of raloxifene hydrochloride.
    Saitta A; Morabito N; Frisina N; Cucinotte D; Corrado F; D'Anna R; Altavilla D; Squadrito G; Minutoli L; Arcoraci V; Cancellieri F; Squadrito F
    Cardiovasc Drug Rev; 2001; 19(1):57-74. PubMed ID: 11314601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of raloxifene and its clinical applications in osteoporosis.
    Maricic M; Gluck O
    Expert Opin Pharmacother; 2002 Jun; 3(6):767-75. PubMed ID: 12036416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of raloxifene (Evista) in the treatment and prevention of postmenopausal osteoporosis].
    Korsić M
    Reumatizam; 2003; 50(2):55-7. PubMed ID: 15098379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal effects of selective oestrogen receptor modulators (SERMs).
    Díez JL
    Hum Reprod Update; 2000; 6(3):255-8. PubMed ID: 10874570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
    Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
    J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
    Johnston CC; Bjarnason NH; Cohen FJ; Shah A; Lindsay R; Mitlak BH; Huster W; Draper MW; Harper KD; Heath H; Gennari C; Christiansen C; Arnaud CD; Delmas PD
    Arch Intern Med; 2000 Dec 11-25; 160(22):3444-50. PubMed ID: 11112238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raloxifene for older women: a review of the literature.
    Hansdóttir H
    Clin Interv Aging; 2008; 3(1):45-50. PubMed ID: 18488877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.